PHILADELPHIA, Aug. 27, 2007 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) today provided updates on Alferon N(tm) in connection with West Nile Virus (WNV) and on its flagship pharmaceutical, Alferon N Injection(r) in treating human papilloma virus (HPV) through its specialty pharmacy agreement with Armada Health Care.
